Table S8 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Wang, Peng; Sun, Xin; He, Xueting; Kang, Di; Liu, Xiaoyu; Liu, Dan; Li, Amin; Yang, Guiqun; Lin, Yiwei; Li, Sujing; Wang, Yinxiang; Wang, Yanping

doi:10.1158/2767-9764.29071245

Table S8 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

journal contribution

posted on 2025-05-15, 12:17 authored by Peng Wang, Xin Sun, Xueting He, Di Kang, Xiaoyu Liu, Dan Liu, Amin Li, Guiqun Yang, Yiwei Lin, Sujing Li, Yinxiang Wang, Yanping Wang

<p>Table S8 shows cell viability IC50 values in Ba/F3 engineered RAS cell lines.</p>

History

Related Materials

1.
DOI - Is supplement to Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

ARTICLE ABSTRACT

Glecirasib potently and selectively inhibits KRAS G12C and reduces ERK and AKT phosphorylation in KRAS G12C–mutant cancer cells, further inducing cell-cycle arrest and apoptosis. Glecirasib monotherapy leads to tumor regression in KRAS G12C–mutant animal models and shows synergistic effects with cetuximab or JAB-3312 (sitneprotafib).

Usage metrics

Keywords

Cellular Responses To Anticancer Drugs Drug Mechanisms Pharmacology Cellular pharmacology Pharmacokinetics and pharmacodynamics Small Molecule Agents

Licence

CC BY

Table S8 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports